Seer (SEER)
NASDAQ:SEER
Want to see SEER full AI Analyst Report?
SEER Stock Chart & Stats
$2.00
-$0.06(-2.24%)
At close: 4:00 PM EST
$2.00
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$1.65 - $2.41
Previous CloseN/A
Volume76.55K
Average Volume (3M)113.15K
Market Cap
$106.11M
Enterprise Value$78.53M
Total Cash (Recent Filing)$166.67M
Total Debt (Recent Filing)$23.03M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding54,981,552
10 Day Avg. Volume70,395
30 Day Avg. Volume113,152
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.41
Price to Sales (P/S)6.52
P/FCF Ratio-2.27
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit10.82
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$4.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.12
Revenue Forecast (FY)$17.05M
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayA large cash balance provides a durable runway to fund commercialization, R&D and legal defense without immediate dilution. This cushion gives management time to build instrument utilization and consumable pull‑through, supporting execution toward break‑even and reducing short‑term financing pressure.
Robust IP Estate & Active DefenseA substantial patent portfolio and favorable PTAB outcome protect core nanoparticle enrichment tech, creating a structural deterrent to copycats. Strong IP supports long‑term differentiation, pricing power for consumables and the potential for exclusionary remedies that defend market share and margin sustainability.
Population-scale Partnerships & ValidationMajor biobank collaborations and doubling of peer‑reviewed publications create durable demand channels and scientific credibility. Population‑scale studies generate recurring consumable needs and create network effects: larger cohorts increase stickiness with biobanks and pharma customers over years.
Bears Say
Small, Volatile RevenueRevenue remains small and lumpy, driven by academic funding cycles and irregular service projects. Such volatility hinders absorption of fixed costs, delays scale benefits for gross margin targets, and makes forecasting and commercial scalability structurally more difficult over the medium term.
Persistent Negative Cash FlowContinued negative operating and free cash flow forces reliance on cash reserves or external financing to sustain operations. Even with improved burn versus prior years, structural cash consumption limits flexibility, raises refinancing risk over the medium term, and constrains reinvestment cadence.
Competitive Pressure And Related CostsEntrant imitators can structurally compress pricing and slow adoption by forcing extra market education. The company’s defensive litigation and professional expense run‑rate both raise SG&A and distract commercial teams, weighing on margin recovery and go‑to‑market efficiency over multiple quarters.
Seer News
SEER FAQ
What was Seer’s price range in the past 12 months?
Seer lowest stock price was $1.65 and its highest was $2.41 in the past 12 months.
What is Seer’s market cap?
Seer’s market cap is $106.11M.
When is Seer’s upcoming earnings report date?
Seer’s upcoming earnings report date is Aug 06, 2026 which is in 67 days.
How were Seer’s earnings last quarter?
Seer released its earnings results on May 13, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.005.
Is Seer overvalued?
According to Wall Street analysts Seer’s price is currently Undervalued.
Does Seer pay dividends?
Seer does not currently pay dividends.
What is Seer’s EPS estimate?
Seer’s EPS estimate is -0.22.
How many shares outstanding does Seer have?
Seer has 54,981,552 shares outstanding.
What happened to Seer’s price movement after its last earnings report?
Seer reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -1.13%.
Which hedge fund is a major shareholder of Seer?
Currently, no hedge funds are holding shares in SEER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (100.00% Upside)
$4.00 (100.00% Upside)
Hedge Fund Trend
Decreased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.34%
12-Months-Change
Fundamentals
Return on Equity
-26.58%
Trailing 12-Months
Asset Growth
-21.63%
Trailing 12-Months
Company Description
Seer
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
SEER Company Deck
SEER Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear short-term commercial and margin headwinds (33% YoY revenue decline, compressed gross margin to 35%, negative free cash flow) with multiple strategic positives: rapidly expanding scientific validation (publications doubled YoY), major population-scale biobank partnerships (PRECISE-SG100K and others), continued product and analytics innovation (SP200, Proteograph One Assay, next-gen detector, Raviant DIA), meaningful operating expense reductions (~20% YoY), improved net loss, strong cash position ($219.5M) and active share repurchases. Management reaffirmed full-year guidance and is taking defensive IP/legal actions against imitators while adding seasoned commercial leadership to drive commercialization. Overall, the call signals durable long-term opportunity and disciplined financial management but acknowledges near-term revenue and margin pressures.View all SEER earnings summariesSEER Stock 12 Month Forecast
Average Price Target
$4.00
▲(100.00% Upside)
Technical Analysis
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
TScan Therapeutics
―
Cognition Therapeutics
―
Ownership Overview
13.71% Insiders
7.35% Mutual Funds
20.85% Other Institutional Investors
54.09% Public Companies and
Individual Investors